Entrada Therapeutics, Inc.
TRDA
$8.16
-$0.17-2.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 108.06% | -125.50% | 134.21% | 346.19% | -126.91% |
| Total Depreciation and Amortization | 5.87% | 2.97% | -2.57% | 26.90% | -11.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.15% | -30.24% | 39.21% | -7.93% | 19.30% |
| Change in Net Operating Assets | -180.24% | 30.60% | 64.24% | -1,848.90% | 104.74% |
| Cash from Operations | -30.24% | -160.92% | 256.09% | -535.91% | 83.62% |
| Capital Expenditure | 0.63% | 38.91% | -24.82% | 14.14% | 32.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 165.62% | -252.61% | -186.48% | 34.80% | 974.57% |
| Cash from Investing | 164.35% | -240.10% | -193.25% | 37.31% | 609.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 49,107.28% | -70.14% | 87.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12,845.45% | -100.01% | 49,107.28% | -70.14% | 87.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.61% | -191.77% | 13,906.83% | -94.69% | 156.42% |